INSM

INSM

USD

Insmed Incorporated Common Stock

$182.770-2.510 (-1.355%)

Prix en Temps Réel

Healthcare
Biotechnologie
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$185.280

Haut

$187.880

Bas

$182.580

Volume

1.57M

Fondamentaux de l'Entreprise

Capitalisation Boursière

39.0B

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

2.46M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $60.4Actuel $182.770Haut $197.08

Actualités Connexes

Analyst Upgrades

Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $217

Wells Fargo analyst Tiago Fauth maintains Insmed with a Overweight and raises the price target from $171 to $217.

Voir plus
Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $217
Analyst Upgrades

Goldman Sachs Maintains Buy on Insmed, Raises Price Target to $225

Goldman Sachs analyst Andrea Tan maintains Insmed with a Buy and raises the price target from $196 to $225.

Voir plus
Goldman Sachs Maintains Buy on Insmed, Raises Price Target to $225
Analyst Upgrades

UBS Maintains Buy on Insmed, Raises Price Target to $223

UBS analyst Trung Huynh maintains Insmed with a Buy and raises the price target from $194 to $223.

Voir plus
UBS Maintains Buy on Insmed, Raises Price Target to $223
Analyst Upgrades

RBC Capital Maintains Outperform on Insmed, Raises Price Target to $215

RBC Capital analyst Leonid Timashev maintains Insmed with a Outperform and raises the price target from $139 to $215.

Voir plus
RBC Capital Maintains Outperform on Insmed, Raises Price Target to $215
Analyst Upgrades

B of A Securities Maintains Buy on Insmed, Raises Price Target to $187

B of A Securities analyst Jason Zemansky maintains Insmed with a Buy and raises the price target from $142 to $187.

Voir plus
B of A Securities Maintains Buy on Insmed, Raises Price Target to $187
Analyst Upgrades

UBS Maintains Buy on Insmed, Raises Price Target to $194

UBS analyst Trung Huynh maintains Insmed with a Buy and raises the price target from $140 to $194.

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.